Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

✍ Scribed by Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John JV McMurray

• Book ID: 117304932
• Publisher: The Lancet
• Year: 2009
• Tongue: English
• Weight: 443 KB
• Volume: 373
• Category: Article
• ISSN: 0140-6736
• DOI: 10.1016/s0140-6736(09)60953-3